MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$5,067K
EPS
-$0.08
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
2,231 5,482* 2,611 3,261
General and administrative
1,846 1,369* 1,587 1,364
Total operating expenses
4,077 6,850 4,198 4,625
Total operating loss
-4,077 -6,850* -4,198 -4,625
Interest income
36 29* 39 26
Change in fair value of derivatives
983 1,404* -2,205 -1,096
Interest expense
1,988 1,860* 1,820 1,826
Total other income (expense)
-969 -428* -3,986 -2,896
Net loss
-5,046 -7,278* -8,184 -7,521
Preferred stock dividends
21 -15* 39 63
Net loss applicable to common stockholders
-5,067 -7,263 -8,223 -7,584
Basic EPS
-0.08 -0.113 -0.13 -0.12
Diluted EPS
-0.08 -0.113 -0.13 -0.12
Basic Average Shares
65,782,000 64,057,000 64,205,000 63,447,000
Diluted Average Shares
65,782,000 64,057,000 64,205,000 63,447,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net loss applicableto common...-$5,067K Net loss-$5,046K Preferred stock dividends$21K Total operating loss-$4,077K Total other income(expense)-$969K Change in fair value ofderivatives$983K Interest income$36K Total operatingexpenses$4,077K Interest expense$1,988K Research and development$2,231K General andadministrative$1,846K

GALECTIN THERAPEUTICS INC (GALT)

GALECTIN THERAPEUTICS INC (GALT)